These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 32357912)

  • 21. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging.
    Graf F; Mosch B; Koehler L; Bergmann R; Wuest F; Pietzsch J
    Mini Rev Med Chem; 2010 Jun; 10(6):527-39. PubMed ID: 20370706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.
    Roberts PJ; Kumarasamy V; Witkiewicz AK; Knudsen ES
    Mol Cancer Ther; 2020 Aug; 19(8):1575-1588. PubMed ID: 32546660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
    Goel S; DeCristo MJ; McAllister SS; Zhao JJ
    Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular pathways: CDK4 inhibitors for cancer therapy.
    Dickson MA
    Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
    Klein ME; Kovatcheva M; Davis LE; Tap WD; Koff A
    Cancer Cell; 2018 Jul; 34(1):9-20. PubMed ID: 29731395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
    Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
    Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
    VanArsdale T; Boshoff C; Arndt KT; Abraham RT
    Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
    Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
    Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
    Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
    [No Abstract]   [Full Text] [Related]  

  • 40. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
    Bonelli M; La Monica S; Fumarola C; Alfieri R
    Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.